Welcome to our dedicated page for Disc Medicine news (Ticker: $IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Disc Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Disc Medicine's position in the market.
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) to present company overview at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announced the retirement of Chief Innovation Officer, Dr. Brian MacDonald, after a distinguished 28-year career. Dr. MacDonald will transition to become Chair of Disc’s Scientific Advisory Board. The company expressed gratitude for his leadership and contributions, with plans for him to continue leading as part of the Scientific Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) presented updated results from the phase 2 open-label BEACON study of bitopertin, an orally administered glycine transporter 1 (GlyT1) inhibitor, in patients with erythropoietic protoporphyria (EPP) as an oral presentation at the 65th ASH Annual Meeting. The data showed significant reductions in protoporphyrin IX (PPIX) > 40%, improvements in sunlight tolerance, and positive results from the phase 1b study of DISC-0974 in myelofibrosis patients with anemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) has announced data from initial dose cohorts of its ongoing phase 1b/2 study of DISC-0974, a monoclonal antibody designed to suppress hepcidin by inhibiting the hemojuvelin (HJV) co-receptor, in MF patients with anemia. The initial data demonstrated that treatment with DISC-0974 substantially decreased serum hepcidin, increased serum iron, and resulted in improvements in hemoglobin or reduced transfusion burden across a broad range of MF patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announced the issuance of patent No. 11,813,257 by the USPTO for methods of treating erythropoietic protoporphyrias (EPPs) with glycine transport inhibitors. The patent covers the use of bitopertin, a glycine transport inhibitor, in treating EPP or XLP, with an anticipated expiration in 2041. This further secures IP protection for bitopertin, demonstrating Disc's innovative approach to treating EPP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) reported the completion of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP), with data from all adult patients in BEACON to be presented at ASH 2023. Preliminary pharmacodynamic data from the ongoing phase 1b/2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia will also be presented. Additionally, they initiated a Phase 1 trial of DISC-3405, an anti-TMPRSS6 antibody, and received fast track designation by the FDA for the treatment of polycythemia vera (PV). Financial results for the third quarter ended September 30, 2023, were also reported, with cash and cash equivalents of $370.5 million, increased R&D and G&A expenses, and a net loss of $14.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announces participation in fireside chats at Stifel 2023 Healthcare Conference and presentations at Jefferies London Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. Live webcasts available on ir.discmedicine.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. has completed enrollment for the phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP). The company will present updated interim data from the BEACON study at the upcoming ASH meeting, including a preliminary analysis of the pivotal endpoint. They will also present preliminary data on pharmacodynamic activity from the phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia. The enrollment for both studies was completed in under a year. The company will host a conference call on December 11th to discuss the data and operational plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
-
Rhea-AI Summary
Disc Medicine's Chief Financial Officer, Joanne Bryce, plans to leave the company. A search for a successor has been initiated. Bryce will remain in her role until a replacement is found.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
Rhea-AI Summary
Disc Medicine, Inc. initiates Phase 1 study of DISC-3405 in healthy volunteers, targeting iron reduction in hematologic diseases. Potential therapeutic benefits in polycythemia vera and iron overload conditions. Data updates from other programs expected later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
Disc Medicine, Inc.
Nasdaq:IRON
IRON Rankings
IRON Stock Data
844.00M
13.49M
13.38%
84.99%
7.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
WATERTOWN
About IRON
disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.